Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04478695 -
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT05038800 -
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
|
Phase 1 | |
| Completed |
NCT04176393 -
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
|
Phase 1 | |
| Recruiting |
NCT03850574 -
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04666649 -
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
|
Phase 1 | |
| Recruiting |
NCT04842370 -
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
|
Phase 1 | |
| Active, not recruiting |
NCT02675452 -
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05522192 -
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT03755154 -
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05726110 -
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT03765541 -
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT02623582 -
CD123 Redirected Autologous T Cells for AML
|
Early Phase 1 | |
| Withdrawn |
NCT02215629 -
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 |